Since about 5% of prostate cancers inactivate a PTEN allele by a somatic point mutation (frameshift deletions and insertions, in-frame deletions, missense mutations, or splice-site mutation) [24] and not by a large genomic deletion, it was necessary to consider the effect of any mutation caused by sequence alterations. This evidence concerns the gene PTEN and prostate cancer.